Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Adjusting your budget monthly helps you stay aligned with your financial goals. Explore the benefits of this practice for better control.
23,442 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Investors are flocking to renewable energy stocks as policy support and expanding clean-energy projects push the sect...
Dogecoin broke through a multi-session resistance with a heavy volume burst, prompting traders to eye the next hurdle...
GameStop is weighing a bold move: acquiring eBay. This article breaks down whether does Gamestop's proposed acquisiti...
AWS teams with Coinbase and Stripe to enable USDC payments for AI agents, signaling a major shift in enterprise crypt...
The stock market is rallying, but the financial sector has lagged, a sign of narrow breadth that could portend bigger...
Alpha (AMR) just reported Q1 2026 results, raising questions about growth and margins. This analysis breaks down the ...
GoMining unveils a base-layer Bitcoin payments protocol designed for instant settlements and everyday purchases, plus...
A biotech rally can be thrilling, but a large fund selling into the run-up often signals caution. This article unpack...
Bitcoin holds near a critical level as CME's volatility futures near launch, stoking bets on a push toward the mid-80...
Massive accumulation by large holders and dwindling exchange reserves are fueling debate over a possible Bitcoin bott...
As investors eye Regal Rexnord’s Q1 2026 earnings, the focus turns to demand momentum, margin discipline, and capital...